Stay updated on Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial

Sign up to get notified when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A site-wide notice announces NIH website updates and says that “Super Intelligence” (SI) is being used in place of “Artificial Intelligence” (AI) during the transition.
    Difference
    1%
    Check dated 2026-10-24T22:35:12.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site's displayed revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T22:52:50.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T22:35:07.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record, indicating restricted access to the study details.
    Difference
    18%
    Check dated 2026-09-19T22:28:52.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.5 to v3.6.6, indicating a new version of the page.
    Difference
    0.1%
    Check dated 2026-08-29T20:28:31.000Z thumbnail image
  6. Check
    83 days ago
    Change Detected
    Summary
    A new revision tag indicates the system was updated from v3.6.4 to v3.6.5. This reflects an incremental platform update rather than changes to page content.
    Difference
    0.1%
    Check dated 2026-08-08T17:11:58.000Z thumbnail image

Stay in the know with updates to Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.